Coronary/Structural Heart

American Society For Preventive Cardiology (ASPC) Launches The American Journal Of Preventive Cardiology

JACKSONVILLE, Fla., March 25, 2020 /PRNewswire/ — The American Society for Preventive Cardiology (ASPC) launches the American Journal of Preventive Cardiology, one of the only journals dedicated solely to preventive cardiology in the U.S. “Preventive cardiology has witnessed exponential growth over the past few decades in the available clinical tools and new knowledge. We […]

CardioQuip MCH-1000™ Earns CE Mark Approval

Advanced temperature control technology to help European hospitals fighting COVID-19 outbreak COLLEGE STATION, Texas, March 26, 2020 /PRNewswire/ — CardioQuipTM, LLC, a medical device manufacturer focused on development and commercialization of patient temperature control and cardiovascular perfusion technology announced today it has received CE Mark approval for the MCH-1000TM Modular Cooler-Heater SeriesTM. The MCH-1000 Series of […]

MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic

Reaffirms Second Quarter 2020 Expected Timing for Topline Data from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten and Phase 2a Danicamtiv Study BRISBANE, Calif., March 26, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today provided an update to the status of its clinical programs in the context of the COVID-19 […]

LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting

LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced two abstracts focused on implantable neuromodulation technology for patients with heart failure will be shared at this year’s American College of Cardiology and World Congress of Cardiology Virtual meeting (ACC.20/WCC). In lieu of traditional in-person presentations, ACC.20/WCC will […]

Catasys’ Telehealth-Enabled OnTrak™ Programs See Surge in Enrollment and Engagement Amidst COVID-19 Pandemic

Customer Expansions Continue as Effective Outreach Pool Climbs to 145,000, Up 34% from Q4 2019 SANTA MONICA, Calif.–(BUSINESS WIRE)–Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI-powered and telehealth-enabled, virtualized outpatient healthcare treatment company, today announced that the Company is surpassing a weekly rate of 500 member enrollments for the […]

Foldax® Completes Enrollment in Tria LifePolymer™ Early Feasibility Study

Company demonstrates excellent progress in its surgical aortic heart valve study SALT LAKE CITY–(BUSINESS WIRE)–Foldax® announced today that it has completed initial enrollment in its early feasibility study (EFS) for the Tria LifePolymer™ heart valve. Fifteen patients have been enrolled in 4 participating sites. “The study is progressing well and we […]

MCRA Launches Medical Device U.S. FDA Regulatory & Clinical Trial Advisory Support & Call Center to Assist with the COVID-19 Pandemic

WASHINGTON, March 24, 2020 /PRNewswire/ — MCRA, LLC, a leading medical device advisory firm and CRO with specialization in regulatory affairs, clinical research, reimbursement, compliance, and quality assurance, has implemented a call center to keep medical device manufacturers informed of government and site decisions that impact regulatory submissions, clinical study operations, or quality […]

CHF Solutions’ Aquadex FlexFlow® System is licensed and approved for sale in India

EDEN PRAIRIE, Minn., March 19, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS) today announced the Aquadex FlexFlow system has been licensed and approved for sale in India, making ultrafiltration therapy available for patients suffering from hypervolemia, or fluid overload, in one of the largest countries in the world. “We […]

Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy

– Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents and heterozygous familial hypercholesterolemia (HeFH)[1,2] – Inclisiran reduced LDL-C at 17 months by 52% in patients with ASCVD (ORION-10), 50% for ASCVD and ASCVD risk […]